Results for tag: "Bronchial Spasm Drug"

The Bronchial Spasm Drug market is a subset of the larger Respiratory Drugs market. Bronchial Spasm Drugs are used to treat bronchospasm, a condition in which the airways of the lungs become constricted, making it difficult to breathe. These drugs are typically administered through inhalation, and can be used to treat both acute and chronic bronchospasm. Commonly prescribed Bronchial Spasm Drugs include short-acting beta-agonists, long-acting beta-agonists, anticholinergics, and theophylline. The Bronchial Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Boehringer Ingelheim, Novartis, Sanofi, Pfizer, and Teva Pharmaceuticals. Show Less Read more